Project Grant K08CA308856
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $263K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded Carnegie Mellon University $521,523 on July 6, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate multi-faceted regulation of dynamic sumoylation at alternative lengthening of telomeres (ALT) cancer telomeres. The project, R01CA308360, addresses the lack of therapeutic targets for ALT cancers, which represent a subset of malignancies that extend telomeres through homology-directed repair pathways occurring in...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $137,631 on July 3, 2026, under the Cancer Research Manpower program (CFDA 93.398) to fund research on mutant splicing factor-derived protein isoforms in clonal hematopoietic disorders and antigen presentation. The award funds basic research investigating how somatic mutations in RNA splicing factor genes (U2AF1, SF3B1, and SRSF2) drive myelodysplastic syndromes and related clonal hematopoietic conditions. The...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $444,590 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to evaluate genetic and epigenetic determinants of treatment response in patients with accelerated and blast phase myeloproliferative neoplasms. The research builds on a prior Phase I/II study (MPD-RC 109) testing combination therapy with the JAK1/2 inhibitor ruxolitinib and the hypomethylating agent decitabine in advanced MPN...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $577,331 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to repurpose HSP90 inhibitors as a condensate-directed therapy for receptor tyrosine kinase fusion-driven cancers. The project targets cancers driven by RTK fusions such as EML4-ALK and CCDC6-RET, which account for 3–5 percent of all cancer diagnoses and approximately 225,000 new lung cancer patients annually worldwide. The...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $752,808 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate clonal hematopoiesis as a mechanism of therapeutic resistance in anaplastic thyroid cancer. The research examines how clonal hematopoiesis—the age-related expansion of mutant hematopoietic stem and progenitor cells—drives resistance to BRAF-MEK inhibitor therapy in anaplastic thyroid cancer patients. The project...
- The National Cancer Institute awarded Duke University $395,846 on April 1, 2026, as a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to support research on therapeutic targeting of SMARCAL1 in therapy-resistant gliomas through May 31, 2031. The research addresses alternative lengthening of telomeres (ALT), a telomerase-independent mechanism through which 10–15% of cancers achieve replicative immortality. IDH-mutant astrocytomas, characterized by co-occurring mutations in...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $731,937 on August 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and optimize computational immunology tools for predicting T-cell receptor specificity to peptide-major histocompatibility complex ligands. The project focuses on refining EnFoldX, an ensemble-based algorithm that leverages protein structure prediction models such as AlphaFold3 to jointly fold TCR:PMHC complexes and...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $752,280 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to decode basal cell multipotency as a precursor and therapeutic target in histological transformation across lung cancer subtypes. The award funds research into the molecular and cellular mechanisms driving adenocarcinoma transformation to small cell lung cancer or squamous cell carcinoma histology as a resistance mechanism...